Search Technologies

The National Institute of Child Health and Human Development Endocrinology & Genetics Section seeks parties interested in licensing tumor samples harboring novel stem cell factor FOXD3 variants.

The Section on Translational Neuroscience of NICHD seeks parties interested in licensing and/or collaborative research to co-develop this therapeutic management of Menkes Disease and related copper transport disorders.

In collaboration with the National Cancer Institute (NCI), researchers at The Eunice Kennedy Shriver National Institute on Child Health and Human Development (NICHD) have discovered monoclonal antibodies that bind to matrilin-3, a protein specifically expressed in cartilage tissue, that could be used for treating or inhibiting growth plate disorders, such as a skeletal dysplasia or short stature. The monoclonal antibodies can also be used to target therapeutic agents, such as those for anti-arthritis, to cartilage tissue. NICHD seeks statements of capability or interest from parties interested in collaborative research to co-develop, evaluate, and/or commercialize treatment of skeletal disorders using targeting antibodies.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research and development partners or licensees for novel composite hydrogels that can be used in tissue repair and other applications. Single gel networks used in tissue engineering and tissue repair applications generally become softer and more flaccid as they swell. The gels described in this technology, however, which comprise a swellable crosslinked polymer hydrogel dispersed in a crosslinked polymer matrix, mimic critical material properties of tissue extracellular matrix (ECM), for instance, becoming stiffer and tougher upon swelling.

GSD-Ia is an inherited disorder of metabolism associated with life-threatening hypoglycemia, hepatic malignancy, and renal failure caused by the deficiency of glucose-6-phosphatase-alpha (G6Pase-alpha or G6PC). NICHD seeks parties to license this invention towards commercialization.

Researchers at the National Institute of Child Health and Human Development (NICHD) developed a device simulating a blast shock wave of the type produced by explosive devices such as bombs. The invention allows for the real-time study of blast effects on in vitro cell models. NICHD researchers seek licensing opportunities to further develop this device.

The National Institute of Child Health and Human Development (NICHD) seeks licensing and/or co-development of a colposcope attachment that resolves tissue borne specular flare.

Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seek partners to collaborate on in vitro studies to validate these potential immunomodulators and to conduct in vivo studies in a murine cancer model to determine the effects of ligands (e.g., antibodies) to the proteins on the immune response to cancer cells. Preference will be given to responses received by March 31, 2016.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for development of a new chemical entity and monomeric and oligomeric compound embodiments for development as a male contraceptive.